Heska Corp  

(Public, NASDAQ:HSKA)   Watch this stock  
Find more results for Jason Riley´┐Ż
12.00
0.00 (0.00%)
Real-time:   3:58PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.70 - 14.58
Open     -
Vol / Avg. 0.00/18,768.00
Mkt cap 75.45M
P/E 27.14
Div/yield     -
EPS 0.44
Shares 6.29M
Beta 0.59
Inst. own 31%
Jul 30, 2014
Q2 2014 Heska Corp Earnings Call
Jul 30, 2014
Q2 2014 Heska Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 3.40% -1.20%
Operating margin 4.00% -1.83%
EBITD margin - 1.36%
Return on average assets 3.27% -1.17%
Return on average equity 8.77% -2.49%
Employees 290 -
CDP Score - -

Address

3760 ROCKY MOUNTAIN AVENUE
LOVELAND, CO 80538
United States - Map
+1-970-4937272 (Phone)
+1-970-6193003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. It operates in two segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, vaccines and pharmaceuticals, primarily for canine and feline use. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals and fish. In February 2013, it announced the acquisition of 54.6% interest of Cuattro Veterinary USA, LLC.

Officers and directors

Robert B. Grieve Ph.D. Executive Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Kevin S. Wilson President, Chief Executive Officer
Age: 42
Bio & Compensation  - Reuters
Jason A. Napolitano Chief Financial Officer, Executive Vice President, Secretary
Age: 45
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael J. McGinley Ph.D. President - Biologicals & Pharmaceuticals
Age: 53
Bio & Compensation  - Reuters
Steven M. Asakowicz Executive Vice President - Companion Animal Health Sales
Age: 48
Bio & Compensation  - Reuters
Rodney A. Lippincott Executive Vice President - Companion Animal Health Sales
Age: 40
Bio & Compensation  - Reuters
Nancy Wisnewski Ph.D. Executive Vice President - Product Development and Customer Support
Age: 51
Bio & Compensation  - Reuters
William A. Aylesworth Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
David E. Sveen Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
G. Irwin Gordon Independent Director
Age: 63
Bio & Compensation  - Reuters